Johanna E. Gehin

Oslo, Norway

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 26 publications

Serum drug levels and JCV assay discrepancies after switching from originator to biosimilar natalizumab.

Serum drug levels and JCV assay discrepancies after switching from originator to biosimilar natalizumab.

Journal: BMJ neurology open

Published: December 01, 2025

Cost-effectiveness of proactive therapeutic drug monitoring of maintenance infliximab treatment in patients with immune-mediated inflammatory diseases: results from a randomised controlled trial.

Cost-effectiveness of proactive therapeutic drug monitoring of maintenance infliximab treatment in patients with immune-mediated inflammatory diseases: results from a randomised controlled trial.

Journal: RMD open

Published: September 08, 2025

The Effect of Certolizumab Pegol Dose and Dose Changes on Plasma Trough Levels: Data From a Randomized Phase III Trial.

The Effect of Certolizumab Pegol Dose and Dose Changes on Plasma Trough Levels: Data From a Randomized Phase III Trial.

Journal: Therapeutic drug monitoring

Published: April 30, 2025

Newly-diagnosed rheumatoid arthritis patients have elevated levels of plasma extracellular vesicles with protein cargo altered towards inflammatory processes.

Newly-diagnosed rheumatoid arthritis patients have elevated levels of plasma extracellular vesicles with protein cargo altered towards inflammatory processes.

Journal: Scientific reports

Published: December 16, 2024

Proactive therapeutic drug monitoring of biologic drugs in adult patients with inflammatory bowel disease, inflammatory arthritis, or psoriasis: a clinical practice guideline.

Proactive therapeutic drug monitoring of biologic drugs in adult patients with inflammatory bowel disease, inflammatory arthritis, or psoriasis: a clinical practice guideline.

Journal: BMJ (Clinical research ed.)

Published: October 28, 2024

Therapeutic serum level for adalimumab in rheumatoid arthritis: explorative analyses of data from a randomised phase III trial.

Therapeutic serum level for adalimumab in rheumatoid arthritis: explorative analyses of data from a randomised phase III trial.

Journal: RMD open

Published: August 16, 2024

Influence of rheumatoid factor levels and TNF inhibitor structure on secondary nonresponse in rheumatoid arthritis patients.

Influence of rheumatoid factor levels and TNF inhibitor structure on secondary nonresponse in rheumatoid arthritis patients.

Journal: Frontiers in medicine

Published: July 08, 2024

Managing hemolysis in serum neuron-specific enolase measurements - an automated algorithm for routine practice.

Managing hemolysis in serum neuron-specific enolase measurements - an automated algorithm for routine practice.

Journal: Scandinavian journal of clinical and laboratory investigation

Published: June 10, 2024

Therapeutic Drug Monitoring: A Tool to Optimize Treatment of Inflammatory Joint Diseases.

Therapeutic Drug Monitoring: A Tool to Optimize Treatment of Inflammatory Joint Diseases.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: October 23, 2023

Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trials.

Clinical consequences of infliximab immunogenicity and the effect of proactive therapeutic drug monitoring: exploratory analyses of the randomised, controlled NOR-DRUM trials.

Journal: The Lancet. Rheumatology

Published: September 14, 2023

Influence of rheumatoid factor on serum drug levels of TNF inhibitors with different structures in rheumatoid arthritis.

Influence of rheumatoid factor on serum drug levels of TNF inhibitors with different structures in rheumatoid arthritis.

Journal: Clinical and experimental rheumatology

Published: May 30, 2023

Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseases.

Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseases.

Journal: Rheumatology (Oxford, England)

Published: May 12, 2023

Showing 1-12 of 26

Last Updated: 09/26/2026